Open an account

Kiora Pharmaceuticals

KPRX · NASDAQ

$2.33−$0.05 (−2.10%)TodayMarket closed ·
Prev close $2.38

About KPRX

Kiora Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. The company is headquartered in Encinitas, California and currently employs 13 full-time employees. The company went IPO on 2015-02-13. The firm is engaged in developing KIO-301, a vision-restoring small molecule that acts as a photoswitch specifically created to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). The company is also developing KIO-104 for the treatment of retinal inflammatory diseases, including Diabetic Macular Edema (DME) and Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-104 is a non-steroidal small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH) formulated for intravitreal delivery and is ideally suited to suppressing overactive T-cell activity to treat the underlying inflammation. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases.

Employees
13
Headquarters
Encinitas, California
Listed
Feb 13, 2015
Sector
Health Care
Industry
Pharmaceuticals
Website
kiorapharma.com

KPRX key statistics

Market cap
10.31M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
11.41K
Volume
23.45K
Open price
$2.38
High today
$2.41
Low today
$2.32
52 Week high
$2.91
52 Week low
$1.76

Kiora Pharmaceuticals (KPRX) at a glance

Kiora Pharmaceuticals (KPRX) last traded at $2.33, with a market cap of 10.31M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $2.32 and $2.41. The current price is 0.4% above the day's low and 3.3% below its high.

Volume so far is 23.45K shares, above the average of 11.41K shares a day.

Over the past year Kiora Pharmaceuticals has ranged from $1.76 to $2.91, and now sits 49% of the way up that range.

Kiora Pharmaceuticals met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.34 per share against an estimate of -$0.6324.

KPRX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 40.8% on average.

  1. Q3 FY24: reported -$0.81 per share against an estimate of -$0.7793
  2. Q4 FY24: reported -$1.04 per share against an estimate of -$0.561
  3. Q1 FY25: reported -$0.52 per share against an estimate of -$0.6834
  4. Q2 FY25: reported -$0.54 per share against an estimate of -$0.6171
  5. Q3 FY25: reported $0.01 per share against an estimate of -$0.7497
  6. Q4 FY25: reported -$1.59 per share against an estimate of -$0.6834
  7. Q1 FY26: reported -$0.58 per share against an estimate of -$0.7242
  8. Q2 FY26: reported -$0.34 per share against an estimate of -$0.6324

KPRX news

  • Press releaseNewsfile

    Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium

  • Press releaseNewsfile

    Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model

  • Press releasePRNewswire

    Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders

  • Press releaseBusiness Wire

    Vicarious Surgical Announces Leadership Transition: Stephen From, Healthcare Industry Veteran, Appointed Chief Executive Officer

Similar companies

Companies in the same industry as Kiora Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.